EarliTec Diagnostics Raises $19.5M to Advance Autism Diagnosis and Treatment in Children

EarliTec Diagnostics Raises $19.5M to Advance Autism Diagnosis and Treatment in Children

EarliTec Dx raises $19.5M for products for children with Autism Spectrum Disorder (ASD) and early childhood vulnerabilities,

This round of financing will be used to support filing with the U.S. Food and Drug Administration (FDA) for 510K clearance, as well as commercialization of the company’s first product, the EarliPoint® Evaluation for ASD, which received breakthrough status in April 2021. With technology developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, the company has completed clinical trials with more than 1,500 children—receiving breakthrough status for the EarliPoint® system in April of last year.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Mar 28, 2024 at 3:00am